Changing winds in refractory autoimmune disease in children
Authors:
- Caroline A. LindemansCLCaroline A. Lindemans
- Annet van RoyenARAnnet van Royen
- Jaap J. BoelensJBJaap J. Boelens
- Berent J. PrakkenBPBerent J. Prakken
- Nico WulffraatNWNico Wulffraat
- 1 May 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 24 (3) , 267-273
Abstract
To give an overview of the recent advances in cellular therapies in pediatric autoimmune diseases. Since the 1990s, autologous hematopoietic stem cell transplantation (HSCT) has been applied in more than 800 patients with severe refractory autoimmune diseases. Despite obvious successes, it is clear that the autoimmune disease in many of these patients relapsed. Anecdotal reports of allogeneic HSCT seem promising. Furthermore, several trials exploring the use of mesenchymal stem or stromal cells (MSC) for therapy of refractory autoimmune diseases have been published. Mostly allogeneic MSC are used at a dose of 1 million/kg intravenously. Even though promising new agents have become available for the treatment of autoimmune disease (AID), some arthritis patients fail to achieve even a modest improvement. Cellular therapies may be the answer in steering the immune system into a more tolerant path. Autologous HSCT after an immunoablative pretreatment allows rebuilding of a partially reset immune system. A small group of severely refractory pediatric patients is unlikely to benefit from immunosuppressive therapies alone. With allogeneic transplant becoming safer and overall mortality numbers much lower in pediatric transplantation, allogeneic HSCT might become the more sensible option for this small group of refractory patients. A promising new cellular therapy is the use of MSC. The working mechanism is immunomodulatory, through induction of Tregs. Although their place is still to be determined, they may provide a safer alternative to severely compromised children or as an adjuvant therapy earlier in the disease. We have implemented cellular therapy options for our refractory pediatric AID patients. We consider progressing to cellular therapies in severely affected individuals, to ultimately cure their disease. Our cellular therapy protocols are provided in this review.Keywords
This publication has 32 references indexed in Scilit:
- Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: Report of five casesArthritis & Rheumatism, 2011
- Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosusLupus, 2010
- Allogeneic hematopoietic SCT for patients with autoimmune diseasesBone Marrow Transplantation, 2009
- Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2008
- Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137LLeukemia, 2007
- Synovial fluid recruits human mesenchymal progenitors from subchondral spongious bone marrowJournal of Orthopaedic Research, 2007
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitroRheumatology, 2006
- Adult stem cells in the treatment of autoimmune diseasesRheumatology, 2006
- Rheumatoid arthritis therapy after tumor necrosis factor and interleukin‐1 blockadeArthritis & Rheumatism, 2003